AbCellera Biologics Inc. is a biotechnology company that specializes in the discovery and development of therapeutic antibodies. Founded in 2012 and headquartered in Vancouver, Canada, AbCellera utilizes an AI-powered platform to analyze vast databases of natural immune responses, enabling the identification of antibodies that can be developed into drugs. The company also creates next-generation transgenic mice to produce fully human antibodies for therapeutic candidates. AbCellera's approach addresses the challenges of traditional antibody discovery, allowing for faster and more precise identification of optimal clinical candidates. The company has established partnerships with various pharmaceutical firms, including a notable agreement with Eli Lilly and Company, which enhances its capabilities in antibody screening and development. Through its integrated platform, AbCellera combines advanced technology and expertise to streamline the drug discovery process, ultimately aiming to deliver effective therapeutics to patients more efficiently.
Trianni, Inc. develops and provides a humanized monoclonal antibody platform. The company offers The Trianni Mouse, an antibody discovery platform which provides human antibody repertoire for the facile isolation of monoclonal antibodies. Trianni, Inc. was founded in 2010 and is based in San Francisco, California. As of November 6, 2020, Trianni, Inc. operates as a subsidiary of AbCellera Biologics Inc..
Invetx, Inc. is a biotechnology company based in Boston, Massachusetts, that specializes in developing protein-based therapeutics for animal health care. The company focuses on creating biopharmaceutical solutions that apply human biotechnology advancements to veterinary medicine. Invetx aims to build a premier innovation platform for veterinary therapeutics, collaborating with leading biotechnology firms, investors, and industry experts. Its team, which includes veterinary scientists and clinicians, is dedicated to discovering and developing a diverse portfolio of therapies and technologies. The company's vision is to enhance health outcomes for both pets and farm animals by leveraging biopharma technologies in the global animal health industry.
Dualogics - OrthoMab
Acquisition in 2020
OrthoMab is an operator of a bispecific platform dedicated to creating improved antibody therapies. The company specializes in producing antibodies using standard production and purification techniques which are available in flexible formats that can be tailored to specific target biology and mechanisms of action.
Invetx, Inc. is a biotechnology company based in Boston, Massachusetts, that specializes in developing protein-based therapeutics for animal health care. The company focuses on creating biopharmaceutical solutions that apply human biotechnology advancements to veterinary medicine. Invetx aims to build a premier innovation platform for veterinary therapeutics, collaborating with leading biotechnology firms, investors, and industry experts. Its team, which includes veterinary scientists and clinicians, is dedicated to discovering and developing a diverse portfolio of therapies and technologies. The company's vision is to enhance health outcomes for both pets and farm animals by leveraging biopharma technologies in the global animal health industry.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.